Is the U.S. clinical trial infrastructure optimized to meet the current and growing enrollment needs?

Alzheimer’s disease (AD) clinical development continues to expand with 28 drugs in Phase 3, 74 in Phase 2, and 24 in Phase 1 in 2021. This study seeks to investigate how the U.S. clinical trial infrastructure is prepared to meet the current and growing enrollment needs. We aim to evaluate the overlap between regional density of persons with dementia (PWD) and trial site service areas with attention to how coverage gaps impact the ability to enroll study participants representative of the national population diagnosed with AD.